Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VBI-1901 |
Synonyms | |
Therapy Description |
VBI-1901 is a vaccine comprising enveloped virus-like particles that contain GM-CSF linked to the cytomegalovirus antigens, glycoprotein B (gB) and phosphoprotein 65 (pp65), thereby potentially stimulating an immune attack against gB and pp65-expressing cancer cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VBI-1901 | VBI1901|VBI 1901 | VBI-1901 is a vaccine comprising enveloped virus-like particles that contain GM-CSF linked to the cytomegalovirus antigens, glycoprotein B (gB) and phosphoprotein 65 (pp65), thereby potentially stimulating an immune attack against gB and pp65-expressing cancer cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03382977 | Phase I | VBI-1901 | Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | Recruiting | USA | 0 |